A Phase 1/2 interventional study of Abatacept or Placebo (both as IV & SC Solution) and Abatacept or Placebo (both as IV & SC Solution) in Rheumatoid Arthritis, sponsored by Bristol-Myers Squibb. Completed at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-08.
Sponsored by Bristol-Myers Squibb · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 63 studies testing abatacept in Arthritis, Rheumatoid — 3 open to participants now, 4 under way, 3 of them phase 3. Abatacept · Arthritis, Rheumatoid.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, this one is the 38th largest by enrollment, is one of 3 that started in 2006, is one of 2 in phase 1/2, and was the 11th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.
Browse Arthritis, Rheumatoid studies →3 of the 63 studies testing abatacept in Arthritis, Rheumatoid are open now, in 3 countries. Recruiting first, the newest first:
NYU Langone Health · Sites in United States
Ages 18+
University Hospital, Montpellier · Sites in France, Monaco
Ages 18+
University of Nebraska · Sites in United States
Ages 19+
By country, each count listing its studies:
Abatacept: first FDA approval 2005 (ORENCIA), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
63 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 12 · Phase 3 27 · Phase 4 16
First in 2000; this study’s year is marked. 3 started in 2006.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 87 is close to the median of 96 across 2,222 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 119 across the 63 interventional studies. Of the 46 that completed or were terminated, 32 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
36 of 63 have an industry lead sponsor. The 10 most frequent:
Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.
Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.
92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb: 4 open now, 8 under way, 2 of them phase 3. Of 82 finished, 31 (38%) have results posted.
Among the 92 studies in Arthritis, Rheumatoid by Bristol-Myers Squibb, this one is the 37th largest by enrollment of the 58 interventional ones that give a count, is one of 5 that started in 2006, is one of 4 in phase 1/2, and was the 12th registered.
Bristol-Myers Squibb’s Arthritis, Rheumatoid studies by the year they started, since 2000.
1 of the studies testing abatacept in Arthritis, Rheumatoid that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
Add it to your calendar (.ics) → With an account.
Among the 63 studies testing abatacept in Arthritis, Rheumatoid, from their registry updates:
Among Bristol-Myers Squibb’s 92 in Arthritis, Rheumatoid:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to study serum levels of Abatacept after subcutaneous dosing in subjects with RA.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Abatacept or Placebo (both as IV & SC Solution)
Drug: Abatacept or Placebo (both as IV & SC Solution)
Drug: Abatacept or Placebo (both as IV & SC solution)
Drug: Abatacept or Placebo (both as IV & SC solution)
Drug: Abatacept or Placebo (both as IV & SC solution)
Long Term
Drug: Abatacept
Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 75 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
Also known as: Orencia
Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 500 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
Also known as: Orencia
Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 750 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
Also known as: Orencia
Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 125 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
Also known as: Orencia
Abatacept \& Placebo as IV \& SC solution, IV/SC, Abatacept 1000 mg IV (Day 1)/Abatacept 200 mg SC (once weekly for 12 weeks) or Placebo IV(Day 1)/Placebo SC (once weekly for 12 weeks), 12 weeks then long term extension (LTE).
Also known as: Orencia
Solution in pre-filled syringes, Subcutaneously, 125 mg, Weekly
Short Term Period: Steady-state Trough Serum Concentration (Cmin) of Abatacept Following Weekly Subcutaneous Dosing in Participants With Active Rheumatoid Arthritis Receiving Disease Modifying Anti-rheumatic Drugs (DMARDS)
Participants received abatacept while also receiving DMARDS over a short term (ST) 12 Week period. To eliminate contribution from the IV loading dose of abatacept during the short term study period, Cmin values were selected from Days 71 to 85, when contribution from IV was negligible. Minimum trough serum concentration of abatacept (Cmin) was measured in micrograms/milliliter (µg/mL). Data are presented by treatment the participant actually received, not by what they were randomized to receive.
Time frame: Days 71 to 85
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, Discontinuations Due to Adverse Events Reported During the Variable Dosing Phase of the Long Term Period (LTE)
AEs during variable dose phase of LTE + 56 days post last dose in the variable dose phase or start of the fixed dose phase, which ever came first; includes deaths reported during the variable dose phase including those that occurred greater than 56 days after last dose. Medical Dictionary for Regulatory Activities (MedDRA) version: 15.1. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization (included hospitalizations for elective surgical procedures). Treatment-related=having certain, probable, possible, or missing relationship to study drug. Data presented by treatment the participant was randomized to and not what they actually received.
Time frame: Day 85 to 56 days post last dose
Number of Participants With Pre-specified AEs of Special Interest in the Variable Dosing Phase of Long Term Extension (LTE)
LTE period with variable abatacept dosing starting on Day 85 and continuing until Day 533 when LTE fixed dosing started. AEs of special interest: infection and/or infestation; neoplasms (malignant); pre-specified autoimmune disorder; infusional AEs (peri-infusional: pre-specified AEs occurring during first 24 hours (hrs) after start of the IV loading dose; acute infusional: pre-specified AEs occurring during the first hour after the start of the IV loading dose; systemic injection site reactions (SIR): pre-specified AEs for SIR; local injection site reaction: pre-specified AEs for local site reaction. Data are presented by treatment the participant was randomized to and not what they actually received.
Time frame: Day 85 to Day 533
Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs), Deaths, Discontinuations Due to Adverse Events Summarized Over the Entire Long Term Extension (LTE) Period (Both Variable and Fixed Dosing)
On Day 85 participants rolled over into the LTE with variable dose phase first and at Day 533, a fixed dose phase of 125 mg abatacept SC weekly, irrespective of body weight. This summary includes AEs reported during entire LTE treatment plus 56 days post last dose; includes all deaths reported during the LTE including those that occurred greater than 56 days after last dose. MedDRA version: 15.1. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization (also included hospitalizations for elective surgical procedures). Treatment-related=having certain, probable, possible, or missing relationship to study drug.
Time frame: Day 533 to 56 Days Post last dose
Short Term Period: Peak Serum Concentration (Cmax) of Abatacept at Steady State in Participants With Rheumatoid Arthritis Receiving DMARDS
Peak serum concentration (Cmax) of abatacept after weekly SC administration was determined between the SC dosing interval from Day 71 to 78. Abatacept in human serum was measured by enzyme-linked immunosorbent assay (ELISA). Lower limit of quantification (LLOQ) was 0.001, Upper limit of quantification (ULOQ) was 0.030. Cmax measured in micrograms per milliliter(µg/mL). Data are presented by treatment the participant actually received, not by what they were randomized to receive.
Time frame: Day 71 to Day 78
Short Term Period: Area Under the Curve (AUC) in Time Interval of 7 Days [AUC(TAU)] of Abatacept in Participants With Rheumatoid Arthritis Receiving DMARDS
The steady-state pharmacokinetic parameter AUC(TAU) of abatacept after weekly SC administration was determined between the SC dosing interval from Day 71 to 78 (TAU=7 days). Abatacept in human serum was measured by enzyme-linked immunosorbent assay (ELISA). Lower limit of quantification (LLOQ) was 0.001; Upper limit of quantification (ULOQ) was 0.030. AUC(TAU) measured in in micrograms\*hours per milliliter (µg\*h/mL). Data are presented by treatment the participant actually received, not by what they were randomized to receive.
Time frame: Day 71 to Day 78
Short Term Period: Summary of Adverse Events (AEs), Serious AEs, Deaths, and Discontinuations Due to AEs During 12 Weeks of Treatment With Either Abatacept or Placebo
Number of Participants with Adverse events (AEs), Serious AEs, discontinuations due to AEs, or Deaths occurring while participant was on treatment from Day 1 (treatment) to Day 85 or early termination from the study. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization (also included hospitalizations for elective surgical procedures). Data are presented by treatment the participant actually received, not by what they were randomized to receive.
Time frame: Day 1 to Day 85 (or early termination)
Short Term Period: Number of Participants With Pre-specified Adverse Events (AEs) of Special Interest After Administration of Abatacept or Placebo Over 12 Weeks
AEs of special interest: infection and/or infestation; neoplasms (benign, malignant, unspecified; autoimmune disorder; infusional AEs (peri-infusional: AEs occurring during first 24 hours (hrs) after start of the IV loading dose; acute infusional: AEs occurring during the first hour after the start of the IV loading dose; injection site AEs: AEs occurring at the site of the SC injection. Data are presented by treatment the participant actually received, not by what they were randomized to receive.
Time frame: Day 1 to Day 85 (or early termination)
Short Term Period: Mean Percent Change From Baseline on Day 85 in Participants Positive for Serum Rheumatoid Factor During Abatacept or Placebo Administration
Serum samples were obtained on Days 1, 8, 15, 29, 57 and day of discharge (Day 85 or earlier) for determination of presence of rheumatoid factor (RF). Baseline was defined as Day 1 to calculate percent change. Lower limit of quantitation (LLQ) was 5 Units/milliliter (U/mL). Values below LLQ were set to 2.5 U/mL. Data are presented by treatment the participant actually received, not by what they were randomized to receive.
Time frame: Day 1 to Day 85 (or early termination)
Short Term Period: Number of Participants With Laboratory Abnormalities in Hematology at Baseline (Day 1) to End of Period (Day 85)
Blood samples were obtained: At screening, within 24 hours prior to study drug administration on Day 1, on Days 15, 29, 57 and at study discharge. Baseline (BL) defined as Day 1 prior to treatment. Common toxicity criteria (CTC), Version 3 used to assess parameters. lower limit of normal (LLN). ANC=absolute neutrophil count. White blood cells Grade (Gr) 1:\<LLN to 3.0\*10\^9/L, Gr 2:\<3.0 to 2.0\*10\^9/L, Gr 3:\<2.0 to 1.0\*10\^9/L, Gr 4:\<1.0\*10\^9/L. ANC Gr 1:\<LLN to 1.5\*10\^9/L, Gr 2:\<1.5 to 1.0\*10\^9/L, Gr 3:\<1.0 to 0.5\*10\^9/L, Gr 4:\<0.5\*10\^9/L. Lymphocytes Gr 1: \<LLN to 3.0, Gr 2: 2.0 \< 3.0, Gr 3: 1.0 to \< 2.0, Gr 4; \< 1.0. Platelet count Gr 1:LLN to 75.0\*10\^9/L, Gr 2:\<75.0 to 50.0\*10\^9/L, Gr 3:\<50.0 to 25.0\*10\^9/L, Gr 4:\<25.0 to 10\^9/L. Hemoglobin Gr 1:\<LLN to 10.0 g/dL, Gr 2:\<10.0 to 8.0 g/dL, Gr 3:\<8.0 to 6.5 g/dL, Gr 4:\<6.5 g/dL. Hematocrit (%): \<0.75\*pre-treatment. Data are presented by treatment the participant actually received, not by what they were randomized to receive.
Time frame: Day 1 to Day 85 (or early termination)
Short Term Period: Number of Participants With Laboratory Abnormalities in Serum Chemistry at Baseline and on Treatment up to Day 85
Screening, BL, Days 15, 29, 57, 85 or discharge. Upper limit of normal (ULN). CTC grade (Gr): Alanine transaminase Gr 1:\>ULN to 2.5\*ULN; Gr 2: \>2.5 to 5.0\*ULN; Gr 3: \>5.0 to 20.0\*ULN; Gr 4: \>20.0\*ULN. Aspartate aminotransferase Gr 1: \>ULN to 2.5\*ULN; Gr 2:\>2.5 to 5.0\*ULN; Gr 3: \>5.0 to 20.0\*ULN; Gr 4: \>20.0\*ULN. G-Glutamyl Transferase (U/L) Gr 1:\>ULN to 2.5\*ULN; Gr 2: \>2.5 to 5.0\*ULN; Gr 3: \>5.0 to 20.0\*ULN; Gr 4: \>20.0\*ULN. Alkaline phosphatase (U/L) Gr 1:\>ULN to 2.5\*ULN, Gr2:\>2.5 to 5.0\*ULN, Gr3:\>5.0 to 20.0\*ULN, Gr4: \>20.0\*ULN; creatinine (mg/dL) Gr 1: \>ULN to 1.5\*ULN; Gr 2: \>1.5 to 3.0\*ULN; Gr 3: \>3.0 to 6.0\*ULN; Gr 4: \>10.0\*ULN. Albumin (g/dL) Gr 1:\<LLN to 3.0; Gr 2:\<3.0 to 2.0; Gr 3: \<2.0. Uric Acid (mg/dL)Gr 1: \>1.0 x ULN to 10.0; Gr 4: \>10.0. Sodium (mEq/L) Gr 1: \>ULN to 150; Gr 2: \>150 to 155; Gr 3: \>155 to 160; Gr 4: \> 160. Potassium (mEq/L) Gr 1: \>ULN to 5.5; Gr 2: \>5.5 to 6.0; Gr 3: \>6.0 to 7.0; Gr 4: \>7.0. Data presented by treatment participant actually received.
Time frame: Day 1 to Day 85 (or early termination)
Short Term Period: Mean Change From Baseline at Day 85 in Blood Pressure After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS
Blood pressure (systolic and diastolic) was recorded while the participant was seated during the screening visit, at baseline on Day 1 (prior to administration of IV infusion), prior to administration of all SC injections, and at study discharge (Day 85 or 7 days after the last dose for subjects who terminated early). In addition, blood pressure was recorded at 30 and 60 minutes after the start of the IV infusion on Day 1, and 30 and 60 minutes after all SC injections. Blood pressure was measured in millimeters of mercury (mm Hg). Data are presented by treatment the participant actually received, not by what they were randomized to receive.
Time frame: Day 1 to Day 85 (or early termination)
Short Term Period: Mean Change From Baseline at Day 85 in Pulse Rate After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS
Pulse rate was taken while participant was seated. Pulse rate was recorded during the screening visit, at baseline on Day 1 (prior to administration of IV infusion), prior to administration of all SC injections, and at study discharge (Day 85 or 7 days after the last dose for subjects who terminated early). In addition, vital signs were recorded at 30 and 60 minutes after the start of the IV infusion on Day 1, and 30 and 60 minutes after all SC injections. Pulse rate measured in beats/min (bpm). Data are presented by treatment the participant actually received, not by what they were randomized to receive.
Time frame: Day 1 to Day 85 (or early termination)
Short Term Period: Mean Change From Screening to Day 85 in Electrocardiogram (QT, PR Intervals, QRS Width) After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS
A 12-lead electrocardiogram (ECG) was recorded at screening and at discharge from the study (Day 85 or 7 days after the last dose of study drug for those subjects who terminated early). If there was no history of known cardiac events, an ECG was performed within 6 months of study entry, and documentation was on file, then the screening ECG was not repeated at screening. QT interval, PR interval and QRW Width were reported in milliseconds (msec). If no ECG issues were found in the 12 weeks of the Short Term Period, ECG was not repeated during LTE. Data are presented by treatment the participant actually received, not by what they were randomized to receive.
Time frame: Screening to Day 85 (or early termination)
Short Term Period: Mean Change From Screening at Day 85 in ECG (Heart Rate) After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS
A 12-lead electrocardiogram (ECG) was recorded at screening and at discharge from the study (Day 85 or 7 days after the last dose of study drug for those subjects who terminated early). If there was no history of known cardiac events, an ECG was performed within 6 months of study entry, and documentation was on file, then the screening ECG was not repeated at screening. Heart Rate was reported in beats per minute (bpm). In no ECG issues were found in the 12 weeks of the Short Term Period, ECG was not repeated during LTE. Data are presented by treatment the participant actually received, not by what they were randomized to receive.
Time frame: Screening to Day 85 (or early termination)
Overall Study ST and LTE Periods: Number of Participants With Anti-abatacept Antibodies and/or Anti-cytotoxic T-Lymphocyte Antigen 4 (CTLA4) Antibodies
Assessment of positive antibody response based upon analysis using a validated enzyme-linked immunosorbent assay (ELISA) with a cut-off value. CTLA4 is a protein receptor that downregulates the immune system. Short Term (ST) period was initial 12 Weeks of the study. Overall LTE includes both the variable and fixed abatacept dosing periods and was from the end of the ST period (Day 85) up to 168 days post last dose (treatment in LTE ranged from 4.4 to 74.2 months. Data in the ST period are summarized by the treatment the participants actually received, while the LT period data are summarized by treatment the participant was randomized to receive.
Time frame: ST: Day 1 to Day 85; LTE: Day 85 to 168 days post last dose
Short term (12 week) randomized Period: started January 2006/completed May 2007. Long term extension (LTE): started April 2006/completed July 2012. During LTE: variable dose period and fixed dose period. Patients with active Rheumatoid Arthritis (RA) and receiving disease modifying anti-rheumatic drugs (DMARDS) were eligible to participate.
| Milestone | Group 1: 500 mg IV/75 mg SC | Group 2: 500 mg IV/125 mg SC | Group 3 : 750 mg IV/125 mg SC | Group 4: 1000mg IV/125 mg SC | Group 5: 1000 mg IV/200 mg SC | Placebo | Fixed Dose 125 mg Abatacept |
|---|---|---|---|---|---|---|---|
| Started | 7 | 4 | 29 | 6 | 5 | 17 | 0 |
| Completed | 7 | 3 | 26 | 5 | 5 | 17 | 0 |
| Not completed | 0 | 1 | 3 | 1 | 0 | 0 | 0 |
| Withdrew: Adverse event | 0 | 1 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Poor/non-compliance by participant | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Milestone | Group 1: 500 mg IV/75 mg SC | Group 2: 500 mg IV/125 mg SC | Group 3 : 750 mg IV/125 mg SC | Group 4: 1000mg IV/125 mg SC | Group 5: 1000 mg IV/200 mg SC | Placebo | Fixed Dose 125 mg Abatacept |
|---|---|---|---|---|---|---|---|
| Started | 11 | 0 | 42 | 0 | 10 | 0 | 0 |
| Completed | 8 | 0 | 32 | 0 | 8 | 0 | 0 |
| Not completed | 3 | 0 | 10 | 0 | 2 | 0 | 0 |
| Withdrew: Death | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 2 | 0 | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 2 | 0 | 2 | 0 | 1 | 0 | 0 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Poor or non-compliance | 0 | 0 | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 2 | 0 | 0 | 0 | 0 |
| Milestone | Group 1: 500 mg IV/75 mg SC | Group 2: 500 mg IV/125 mg SC | Group 3 : 750 mg IV/125 mg SC | Group 4: 1000mg IV/125 mg SC | Group 5: 1000 mg IV/200 mg SC | Placebo | Fixed Dose 125 mg Abatacept |
|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 0 | 48 |
| Completed | 0 | 0 | 0 | 0 | 0 | 0 | 35 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 0 | 13 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Adverse event | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 0 | 0 | 0 | 3 |
| Withdrew: Poor or non-compliance | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Other | 0 | 0 | 0 | 0 | 0 | 0 | 1 |
Participants received abatacept while also receiving DMARDS over a short term (ST) 12 Week period. To eliminate contribution from the IV loading dose of abatacept during the short term study period, Cmin values were selected from Days 71 to 85, when contribution from IV was negligible. Minimum trough serum concentration of abatacept (Cmin) was measured in micrograms/milliliter (µg/mL). Data are presented by treatment the participant actually received, not by what they were randomized to receive.
| µg/mL | Group 1: 500 mg IV/75 mg SC (Body Weight < 60 kg) | Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg) | Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg) | Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg) | Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg) |
|---|---|---|---|---|---|
| Day 71 | 22.64 ± 20.13 | 28.03 ± 42.13 | 24.05 ± 40.65 | 16.22 ± 24.39 | 26.52 ± 56.53 |
| Day 78 | 21.66 ± 19.99 | 34.17 ± 29.49 | 24.41 ± 52.35 | 11.57 ± 32.25 | 29.21 ± 52.96 |
| Day 85 | 23.62 ± 31.63 | 36.73 ± 31.64 | 24.93 ± 38.42 | 13.01 ± 41.35 | 27.53 ± 58.87 |
Peak serum concentration (Cmax) of abatacept after weekly SC administration was determined between the SC dosing interval from Day 71 to 78. Abatacept in human serum was measured by enzyme-linked immunosorbent assay (ELISA). Lower limit of quantification (LLOQ) was 0.001, Upper limit of quantification (ULOQ) was 0.030. Cmax measured in micrograms per milliliter(µg/mL). Data are presented by treatment the participant actually received, not by what they were randomized to receive.
| µg/mL | Group 1: 500 mg IV/75 mg SC (Body Weight < 60 kg) | Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg) | Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg) | Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg) | Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg) |
|---|---|---|---|---|---|
| Short Term Period: Peak Serum Concentration (Cmax) of Abatacept at Steady State in Participants With Rheumatoid Arthritis Receiving DMARDS | 26.3 ± 29.5 | 34.9 ± 46.6 | 31.9 ± 42.8 | 14.7 ± 44.3 | 41.7 ± 41.2 |
The steady-state pharmacokinetic parameter AUC(TAU) of abatacept after weekly SC administration was determined between the SC dosing interval from Day 71 to 78 (TAU=7 days). Abatacept in human serum was measured by enzyme-linked immunosorbent assay (ELISA). Lower limit of quantification (LLOQ) was 0.001; Upper limit of quantification (ULOQ) was 0.030. AUC(TAU) measured in in micrograms\*hours per milliliter (µg\*h/mL). Data are presented by treatment the participant actually received, not by what they were randomized to receive.
| µg*h/mL | Group 1: 500 mg IV/75 mg SC (Body Weight < 60 kg) | Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg) | Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg) | Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg) | Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg) |
|---|---|---|---|---|---|
| Short Term Period: Area Under the Curve (AUC) in Time Interval of 7 Days [AUC(TAU)] of Abatacept in Participants With Rheumatoid Arthritis Receiving DMARDS | 4066 ± 22.2 | 6699 ± 20.7 | 4607 ± 38.6 | 2555 ± 30.1 | 5849 ± 40.5 |
AEs during variable dose phase of LTE + 56 days post last dose in the variable dose phase or start of the fixed dose phase, which ever came first; includes deaths reported during the variable dose phase including those that occurred greater than 56 days after last dose. Medical Dictionary for Regulatory Activities (MedDRA) version: 15.1. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization (included hospitalizations for elective surgical procedures). Treatment-related=having certain, probable, possible, or missing relationship to study drug. Data presented by treatment the participant was randomized to and not what they actually received.
| participants | 75 mg SC Abatacept (Body Weight < 60 kg) | 125 mg SC Abatacept (Body Weight <60 to >100 kg) | 200 mg SC Abatacept (Body Weight > 100 kg) |
|---|---|---|---|
| Deaths | 0 | 1 | 0 |
| Participants with SAEs | 2 | 13 | 4 |
| Participants with drug related SAEs | 1 | 2 | 1 |
| Participants discontinued due to SAEs | 0 | 1 | 1 |
| Participants with AEs | 9 | 38 | 9 |
| Participants with drug related AEs | 2 | 20 | 3 |
| Participants discontinued due to AEs | 1 | 2 | 1 |
Number of Participants with Adverse events (AEs), Serious AEs, discontinuations due to AEs, or Deaths occurring while participant was on treatment from Day 1 (treatment) to Day 85 or early termination from the study. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization (also included hospitalizations for elective surgical procedures). Data are presented by treatment the participant actually received, not by what they were randomized to receive.
| participants | Group 1: 500 mg IV/75 mg SC (Body Weight < 60 kg) | Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg) | Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg) | Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg) | Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg) | Placebo (by Body Weight Category) |
|---|---|---|---|---|---|---|
| Deaths | 0 | 0 | 0 | 0 | 0 | 0 |
| Participants with SAEs | 0 | 1 | 1 | 0 | 1 | 0 |
| Participants with AEs | 5 | 3 | 21 | 6 | 5 | 11 |
| Discontinued due to AEs | 0 | 1 | 0 | 1 | 0 | 0 |
AEs of special interest: infection and/or infestation; neoplasms (benign, malignant, unspecified; autoimmune disorder; infusional AEs (peri-infusional: AEs occurring during first 24 hours (hrs) after start of the IV loading dose; acute infusional: AEs occurring during the first hour after the start of the IV loading dose; injection site AEs: AEs occurring at the site of the SC injection. Data are presented by treatment the participant actually received, not by what they were randomized to receive.
| participants | Group 1: 500 mg IV/75 mg SC (Body Weight < 60 kg) | Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg) | Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg) | Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg) | Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg) | Placebo (by Body Weight Category) |
|---|---|---|---|---|---|---|
| Number with Infection/Infestation events | 3 | 1 | 9 | 3 | 1 | 4 |
| Number with malignant neoplasm events | 0 | 0 | 0 | 0 | 0 | 0 |
| Number with autoimmune disorder events | 0 | 0 | 0 | 0 | 0 | 0 |
| Number with acute infusional events | 0 | 0 | 2 | 1 | 0 | 0 |
| Number with peri-infusional events | 0 | 0 | 4 | 3 | 0 | 0 |
| General disorders and injection site events | 0 | 1 | 11 | 3 | 2 | 1 |
Serum samples were obtained on Days 1, 8, 15, 29, 57 and day of discharge (Day 85 or earlier) for determination of presence of rheumatoid factor (RF). Baseline was defined as Day 1 to calculate percent change. Lower limit of quantitation (LLQ) was 5 Units/milliliter (U/mL). Values below LLQ were set to 2.5 U/mL. Data are presented by treatment the participant actually received, not by what they were randomized to receive.
| percentage of change from baseline | Group 1: 500 mg IV/75 mg SC (Body Weight < 60 kg) | Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg) | Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg) | Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg) | Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg) | Placebo (by Body Weight Category) |
|---|---|---|---|---|---|---|
| Short Term Period: Mean Percent Change From Baseline on Day 85 in Participants Positive for Serum Rheumatoid Factor During Abatacept or Placebo Administration | -1.50 ± 43.50 | -8.89 ± 3.14 | -17.69 ± 26.61 | -16.29 ± 16.24 | -19.32 ± 15.21 | 43.72 ± 154.47 |
Blood samples were obtained: At screening, within 24 hours prior to study drug administration on Day 1, on Days 15, 29, 57 and at study discharge. Baseline (BL) defined as Day 1 prior to treatment. Common toxicity criteria (CTC), Version 3 used to assess parameters. lower limit of normal (LLN). ANC=absolute neutrophil count. White blood cells Grade (Gr) 1:\<LLN to 3.0\*10\^9/L, Gr 2:\<3.0 to 2.0\*10\^9/L, Gr 3:\<2.0 to 1.0\*10\^9/L, Gr 4:\<1.0\*10\^9/L. ANC Gr 1:\<LLN to 1.5\*10\^9/L, Gr 2:\<1.5 to 1.0\*10\^9/L, Gr 3:\<1.0 to 0.5\*10\^9/L, Gr 4:\<0.5\*10\^9/L. Lymphocytes Gr 1: \<LLN to 3.0, Gr 2: 2.0 \< 3.0, Gr 3: 1.0 to \< 2.0, Gr 4; \< 1.0. Platelet count Gr 1:LLN to 75.0\*10\^9/L, Gr 2:\<75.0 to 50.0\*10\^9/L, Gr 3:\<50.0 to 25.0\*10\^9/L, Gr 4:\<25.0 to 10\^9/L. Hemoglobin Gr 1:\<LLN to 10.0 g/dL, Gr 2:\<10.0 to 8.0 g/dL, Gr 3:\<8.0 to 6.5 g/dL, Gr 4:\<6.5 g/dL. Hematocrit (%): \<0.75\*pre-treatment. Data are presented by treatment the participant actually received, not by what they were randomized to receive.
| participants | Group 1: 500 mg IV/75 mg SC (Body Weight < 60 kg) | Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg) | Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg) | Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg) | Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg) | Placebo (by Body Weight Category) |
|---|---|---|---|---|---|---|
| Baseline (Day 1 prior to treatment) Total | 4 | 3 | 15 | 1 | 2 | 9 |
| Grade 1 baseline | 4 | 3 | 13 | 1 | 2 | 8 |
| Grade 2 baseline | 0 | 1 | 2 | 0 | 0 | 3 |
| Grade 3 baseline | 0 | 0 | 1 | 0 | 0 | 0 |
| Grade 4 baseline | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 1 after treatment to Day 85 Total | 4 | 4 | 20 | 1 | 4 | 13 |
| Grade 1 on treatment | 4 | 4 | 17 | 1 | 3 | 11 |
| Grade 2 on treatment | 0 | 1 | 6 | 0 | 1 | 3 |
| Grade 3 on treatment | 0 | 0 | 0 | 0 | 0 | 1 |
| Grade 4 on treatment | 0 | 0 | 0 | 0 | 0 | 0 |
Screening, BL, Days 15, 29, 57, 85 or discharge. Upper limit of normal (ULN). CTC grade (Gr): Alanine transaminase Gr 1:\>ULN to 2.5\*ULN; Gr 2: \>2.5 to 5.0\*ULN; Gr 3: \>5.0 to 20.0\*ULN; Gr 4: \>20.0\*ULN. Aspartate aminotransferase Gr 1: \>ULN to 2.5\*ULN; Gr 2:\>2.5 to 5.0\*ULN; Gr 3: \>5.0 to 20.0\*ULN; Gr 4: \>20.0\*ULN. G-Glutamyl Transferase (U/L) Gr 1:\>ULN to 2.5\*ULN; Gr 2: \>2.5 to 5.0\*ULN; Gr 3: \>5.0 to 20.0\*ULN; Gr 4: \>20.0\*ULN. Alkaline phosphatase (U/L) Gr 1:\>ULN to 2.5\*ULN, Gr2:\>2.5 to 5.0\*ULN, Gr3:\>5.0 to 20.0\*ULN, Gr4: \>20.0\*ULN; creatinine (mg/dL) Gr 1: \>ULN to 1.5\*ULN; Gr 2: \>1.5 to 3.0\*ULN; Gr 3: \>3.0 to 6.0\*ULN; Gr 4: \>10.0\*ULN. Albumin (g/dL) Gr 1:\<LLN to 3.0; Gr 2:\<3.0 to 2.0; Gr 3: \<2.0. Uric Acid (mg/dL)Gr 1: \>1.0 x ULN to 10.0; Gr 4: \>10.0. Sodium (mEq/L) Gr 1: \>ULN to 150; Gr 2: \>150 to 155; Gr 3: \>155 to 160; Gr 4: \> 160. Potassium (mEq/L) Gr 1: \>ULN to 5.5; Gr 2: \>5.5 to 6.0; Gr 3: \>6.0 to 7.0; Gr 4: \>7.0. Data presented by treatment participant actually received.
| participants | Group 1: 500 mg IV/75 mg SC (Body Weight < 60 kg) | Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg) | Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg) | Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg) | Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg) | Placebo (by Body Weight Category) |
|---|---|---|---|---|---|---|
| Baseline (Day 1 prior to treatment) Total | 2 | 2 | 6 | 1 | 4 | 7 |
| Grade 1 baseline | 2 | 2 | 5 | 1 | 4 | 7 |
| Grade 2 baseline | 0 | 0 | 1 | 0 | 0 | 2 |
| Grade 3 baseline | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 4 baseline | 0 | 0 | 0 | 0 | 0 | 0 |
| Day 1 (after treatment) to Day 85 Total | 5 | 4 | 18 | 3 | 4 | 15 |
| Grade 1 on treatment | 5 | 0 | 18 | 3 | 3 | 15 |
| Grade 2 on treatment | 1 | 0 | 4 | 0 | 0 | 4 |
| Grade 3 on treatment | 0 | 0 | 0 | 0 | 1 | 1 |
| Grade 4 on treatment | 0 | 0 | 0 | 0 | 1 | 0 |
Blood pressure (systolic and diastolic) was recorded while the participant was seated during the screening visit, at baseline on Day 1 (prior to administration of IV infusion), prior to administration of all SC injections, and at study discharge (Day 85 or 7 days after the last dose for subjects who terminated early). In addition, blood pressure was recorded at 30 and 60 minutes after the start of the IV infusion on Day 1, and 30 and 60 minutes after all SC injections. Blood pressure was measured in millimeters of mercury (mm Hg). Data are presented by treatment the participant actually received, not by what they were randomized to receive.
| mm Hg | Group 1: 500 mg IV/75 mg SC (Body Weight < 60 kg) | Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg) | Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg) | Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg) | Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg) | Placebo (by Body Weight Category) |
|---|---|---|---|---|---|---|
| Change from baseline in Diastolic blood pressure | -5.2 ± 10.0 | 0.0 ± 13.1 | 0.7 ± 7.5 | 3.5 ± 11.2 | -5.4 ± 9.6 | 1.8 ± 8.3 |
| Change from baseline in Systolic blood pressure | -4.0 ± 12.1 | -6.3 ± 6.8 | 0.3 ± 17.8 | -0.8 ± 8.2 | -4.2 ± 10.5 | 0.2 ± 12.1 |
Pulse rate was taken while participant was seated. Pulse rate was recorded during the screening visit, at baseline on Day 1 (prior to administration of IV infusion), prior to administration of all SC injections, and at study discharge (Day 85 or 7 days after the last dose for subjects who terminated early). In addition, vital signs were recorded at 30 and 60 minutes after the start of the IV infusion on Day 1, and 30 and 60 minutes after all SC injections. Pulse rate measured in beats/min (bpm). Data are presented by treatment the participant actually received, not by what they were randomized to receive.
| bpm | Group 1: 500 mg IV/75 mg SC (Body Weight < 60 kg) | Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg) | Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg) | Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg) | Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg) | Placebo (by Body Weight Category) |
|---|---|---|---|---|---|---|
| Short Term Period: Mean Change From Baseline at Day 85 in Pulse Rate After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS | -2.9 ± 10.0 | 0.3 ± 11.1 | -0.6 ± 9.5 | 3.5 ± 10.5 | -11.4 ± 9.0 | -1.0 ± 7.1 |
A 12-lead electrocardiogram (ECG) was recorded at screening and at discharge from the study (Day 85 or 7 days after the last dose of study drug for those subjects who terminated early). If there was no history of known cardiac events, an ECG was performed within 6 months of study entry, and documentation was on file, then the screening ECG was not repeated at screening. QT interval, PR interval and QRW Width were reported in milliseconds (msec). If no ECG issues were found in the 12 weeks of the Short Term Period, ECG was not repeated during LTE. Data are presented by treatment the participant actually received, not by what they were randomized to receive.
| msec | All Treated Participants |
|---|---|
| Change from Screening in QT interval (N=52) | -1.47 ± 24.72 |
| Change from Screening in PR interval (N=51) | 5.28 ± 21.10 |
| Change from Screening in QRS Width (N=52) | 0.22 ± 11.03 |
LTE period with variable abatacept dosing starting on Day 85 and continuing until Day 533 when LTE fixed dosing started. AEs of special interest: infection and/or infestation; neoplasms (malignant); pre-specified autoimmune disorder; infusional AEs (peri-infusional: pre-specified AEs occurring during first 24 hours (hrs) after start of the IV loading dose; acute infusional: pre-specified AEs occurring during the first hour after the start of the IV loading dose; systemic injection site reactions (SIR): pre-specified AEs for SIR; local injection site reaction: pre-specified AEs for local site reaction. Data are presented by treatment the participant was randomized to and not what they actually received.
| participants | 75 mg SC Abatacept | 125 mg SC Abatacept | 200 mg SC Abatacept |
|---|---|---|---|
| Number with Serious Infection/Infestation | 1 | 1 | 2 |
| Number with Malignant Neoplasms | 1 | 5 | 1 |
| Number with Autoimmune Disorder | 0 | 1 | 0 |
| Number with Acute Infusional Event | 0 | 0 | 0 |
| Number with Serious Systemic injection Reaction | 0 | 0 | 0 |
| Number with Local Injection Site Reaction | 0 | 4 | 0 |
A 12-lead electrocardiogram (ECG) was recorded at screening and at discharge from the study (Day 85 or 7 days after the last dose of study drug for those subjects who terminated early). If there was no history of known cardiac events, an ECG was performed within 6 months of study entry, and documentation was on file, then the screening ECG was not repeated at screening. Heart Rate was reported in beats per minute (bpm). In no ECG issues were found in the 12 weeks of the Short Term Period, ECG was not repeated during LTE. Data are presented by treatment the participant actually received, not by what they were randomized to receive.
| bpm | All Treated Participants |
|---|---|
| Short Term Period: Mean Change From Screening at Day 85 in ECG (Heart Rate) After SC Administration of Abatacept or Placebo in Participants With Rheumatoid Arthritis Receiving DMARDS | 0.51 ± 8.43 |
On Day 85 participants rolled over into the LTE with variable dose phase first and at Day 533, a fixed dose phase of 125 mg abatacept SC weekly, irrespective of body weight. This summary includes AEs reported during entire LTE treatment plus 56 days post last dose; includes all deaths reported during the LTE including those that occurred greater than 56 days after last dose. MedDRA version: 15.1. AE=any new unfavorable symptom, sign, or disease or worsening of a preexisting condition that may not have a causal relationship with treatment. SAE=a medical event that at any dose results in death, persistent or significant disability/incapacity, or drug dependency/abuse; is life-threatening, an important medical event, or a congenital anomaly/birth defect; or requires or prolongs hospitalization (also included hospitalizations for elective surgical procedures). Treatment-related=having certain, probable, possible, or missing relationship to study drug.
| participants | SC Abatacept |
|---|---|
| Deaths | 6 |
| Participants with SAEs | 35 |
| Participants with Drug Related SAEs | 7 |
| Participants Discontinued due to SAEs | 3 |
| Participants with AEs | 61 |
| Participants with Drug Related AEs | 34 |
| Participants Discontinued due to AEs | 5 |
Assessment of positive antibody response based upon analysis using a validated enzyme-linked immunosorbent assay (ELISA) with a cut-off value. CTLA4 is a protein receptor that downregulates the immune system. Short Term (ST) period was initial 12 Weeks of the study. Overall LTE includes both the variable and fixed abatacept dosing periods and was from the end of the ST period (Day 85) up to 168 days post last dose (treatment in LTE ranged from 4.4 to 74.2 months. Data in the ST period are summarized by the treatment the participants actually received, while the LT period data are summarized by treatment the participant was randomized to receive.
| participants | Group 1: 500 mg IV/75 mg SC (Body Weight < 60 kg) | Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg) | Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg) | Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg) | Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg) | LTE (Variable and Fixed Dosing Abatacept) |
|---|---|---|---|---|---|---|
| Number with anti-abatacept antibodies | 0 | 0 | 0 | 1 | 0 | 11 |
| Number with anti-CTLA4 antibodies | 0 | 0 | 0 | 0 | 0 | 1 |
Collected over Day 1 of short term study up to 71 months in the long term study.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Abatacept 1000mg IV/125mg SC | — | 1/6 (16.7%) | 6/6 (100%) |
| Abatacept 1000mg IV/200mg SC | — | 0/5 (0%) | 5/5 (100%) |
| Abatacept 500mg IV/125mg SC | — | 1/5 (20%) | 2/5 (40%) |
| Abatacept 500mg IV/75mg SC | — | 0/6 (0%) | 5/6 (83.3%) |
| Abatacept 750mg IV/125mg SC | — | 1/28 (3.6%) | 18/28 (64.3%) |
| Abatacept (LT) 125 mg SC | — | 35/63 (55.6%) | 58/63 (92.1%) |
| Placebo (ST) | — | 0/18 (0%) | 12/18 (66.7%) |
| Event | Abatacept 1000mg IV/125mg SC | Abatacept 1000mg IV/200mg SC | Abatacept 500mg IV/125mg SC | Abatacept 500mg IV/75mg SC | Abatacept 750mg IV/125mg SC | Abatacept (LT) 125 mg SC | Placebo (ST) |
|---|---|---|---|---|---|---|---|
| Wound infectionInfections and infestations | 0/6 | 0/5 | 1/5 | 0/6 | 0/28 | 0/63 | 0/18 |
| Chest discomfortGeneral disorders | 1/6 | 0/5 | 0/5 | 0/6 | 0/28 | 0/63 | 0/18 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 1/6 | 0/5 | 0/5 | 0/6 | 0/28 | 1/63 | 0/18 |
| Sleep apnoea syndromeRespiratory, thoracic and mediastinal disorders | 1/6 | 0/5 | 0/5 | 0/6 | 0/28 | 0/63 | 0/18 |
| Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders | 1/6 | 0/5 | 0/5 | 0/6 | 0/28 | 1/63 | 0/18 |
| Diastolic dysfunctionCardiac disorders | 1/6 | 0/5 | 0/5 | 0/6 | 0/28 | 0/63 | 0/18 |
| Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/6 | 0/5 | 0/5 | 0/6 | 0/28 | 7/63 | 0/18 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 0/6 | 0/5 | 0/5 | 0/6 | 0/28 | 5/63 | 0/18 |
| PneumoniaInfections and infestations | 0/6 | 0/5 | 0/5 | 0/6 | 0/28 | 4/63 | 0/18 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 0/6 | 0/5 | 0/5 | 0/6 | 0/28 | 4/63 | 0/18 |
| Event | Abatacept 1000mg IV/125mg SC | Abatacept 1000mg IV/200mg SC | Abatacept 500mg IV/125mg SC | Abatacept 500mg IV/75mg SC | Abatacept 750mg IV/125mg SC | Abatacept (LT) 125 mg SC | Placebo (ST) |
|---|---|---|---|---|---|---|---|
| HeadacheNervous system disorders | 3/6 | 2/5 | 0/5 | 0/6 | 1/28 | 8/63 | 3/18 |
| Upper respiratory tract infectionInfections and infestations | 1/6 | 0/5 | 0/5 | 0/6 | 3/28 | 22/63 | 2/18 |
| FallInjury, poisoning and procedural complications | 0/6 | 0/5 | 0/5 | 2/6 | 0/28 | 7/63 | 0/18 |
| Oedema peripheralGeneral disorders | 2/6 | 1/5 | 0/5 | 0/6 | 0/28 | 12/63 | 0/18 |
| SinusitisInfections and infestations | 1/6 | 0/5 | 0/5 | 0/6 | 0/28 | 14/63 | 0/18 |
| Back painMusculoskeletal and connective tissue disorders | 0/6 | 0/5 | 0/5 | 1/6 | 3/28 | 14/63 | 3/18 |
| BronchitisInfections and infestations | 0/6 | 0/5 | 0/5 | 1/6 | 0/28 | 13/63 | 1/18 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/6 | 0/5 | 0/5 | 1/6 | 2/28 | 13/63 | 0/18 |
| Urinary tract infectionInfections and infestations | 0/6 | 0/5 | 0/5 | 1/6 | 4/28 | 13/63 | 0/18 |
| Intraocular pressure increasedInvestigations | 0/6 | 1/5 | 0/5 | 0/6 | 0/28 | 1/63 | 0/18 |
Baseline includes all participants enrolled and treated. Baseline parameters are presented for each arm but the total value for baseline mean age and standard deviation (SD) includes all participants in LTE. Data are presented by treatment the participant actually received, not to what they were randomized to receive.
| Age, Continuous(years) | Group 1: 500 mg IV/75 mg SC (Body Weight < 60 kg) | Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg) | Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg) | Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg) | Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg) | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Mean | 72 ± 5 | 64 ± 10 | 59 ± 12 | 51 ± 9 | 55 ± 9 | 59 ± 11 | 60 ± 11 |
| Sex: Female, Male(Participants) | Group 1: 500 mg IV/75 mg SC (Body Weight < 60 kg) | Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg) | Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg) | Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg) | Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg) | Placebo | Total |
|---|---|---|---|---|---|---|---|
| Female | 7 | 3 | 26 | 5 | 4 | 12 | 57 |
| Male | 0 | 1 | 3 | 1 | 1 | 5 | 11 |
| Region of Enrollment(participants) | Group 1: 500 mg IV/75 mg SC (Body Weight < 60 kg) | Group 2: 500 mg IV/125 mg SC (Body Weight < 60 kg) | Group 3 : 750 mg IV/125 mg SC (Body Weight 60-100 kg) | Group 4: 1000mg IV/125 mg SC (Body Weight > 100 kg) | Group 5: 1000 mg IV/200 mg SC (Body Weight > 100 kg) | Placebo | Total |
|---|---|---|---|---|---|---|---|
| United States | 7 | 4 | 29 | 6 | 5 | 17 | 68 |
The record gives a start of Jan 2006, a primary completion of May 2007 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Apr 2014, 6 years 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Abatacept